Tumor Response Rate 8 weeks [clinicaltrials_resource:a0a6392069f003188f465aa11be66b06]
Tumor response rate of stratum B1 participants was evaluated after 1 treatment course of temozolomide plus peginterferon alpha-2b. Complete response (CR) and partial response (PR) confirmed with repeated scan at least 4 weeks apart following completion of course 1 therapy. CR defined as disappearance of all target and non-target lesions with no new lesions detected. If available, no disease must be detected by immunocytology or serum tumor markers. PR defined as at least 30% decrease in disease measurement compared to disease measurement at study entry with no new lesions detected. Progressive disease (PD) defined as at least 20% increase in the disease measurement compared to the smallest disease measurement recorded since start of treatment, or appearance of one or more new lesions. Stable disease defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD compared to smallest disease measurement since start of treatment.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Tumor Response Rate 8 weeks [clinicaltrials_resource:a0a6392069f003188f465aa11be66b06]
Tumor response rate of stratum B1 participants was evaluated after 1 treatment course of temozolomide plus peginterferon alpha-2b. Complete response (CR) and partial response (PR) confirmed with repeated scan at least 4 weeks apart following completion of course 1 therapy. CR defined as disappearance of all target and non-target lesions with no new lesions detected. If available, no disease must be detected by immunocytology or serum tumor markers. PR defined as at least 30% decrease in disease measurement compared to disease measurement at study entry with no new lesions detected. Progressive disease (PD) defined as at least 20% increase in the disease measurement compared to the smallest disease measurement recorded since start of treatment, or appearance of one or more new lesions. Stable disease defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD compared to smallest disease measurement since start of treatment.
Bio2RDF identifier
a0a6392069f003188f465aa11be66b06
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a0a6392069f003188f465aa11be66b06
measure [clinicaltrials_vocabulary:measure]
Tumor Response Rate
time frame [clinicaltrials_vocabulary:time-frame]
description
Tumor response rate of stratum ...... ment since start of treatment.
identifier
clinicaltrials_resource:a0a6392069f003188f465aa11be66b06
title
Tumor Response Rate 8 weeks
@en
type
label
Tumor Response Rate 8 weeks [clinicaltrials_resource:a0a6392069f003188f465aa11be66b06]
@en